Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions

被引:7
作者
Bot, Adrian [1 ]
Marincola, Francesco [2 ]
Smith, Kent A. [3 ]
机构
[1] Kite Pharma Inc, Santa Monica, CA USA
[2] Sidra Med & Res Ctr, Doha, Qatar
[3] Dockside Consultants, Ventura, CA USA
关键词
adoptive T-cell therapy; cancer vaccines; combinatorial therapies; engineered T cells; immune checkpoint blockade; immunotherapy; minimal residual disease; tumor infiltrating lymphocytes; ADOPTIVE CELL TRANSFER; TUMOR-INFILTRATING LYMPHOCYTES; CHRONIC MYELOID-LEUKEMIA; T-CELL; DENDRITIC CELLS; METASTATIC MELANOMA; IN-VIVO; PEPTIDE VACCINATION; ANTITUMOR-ACTIVITY; CLINICAL-TRIAL;
D O I
10.1586/14760584.2013.836908
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Based on lessons learned with various immune interventions, this review aims to provide a constructive framework for repositioning therapeutic cancer vaccination. Intensive research throughout the past decade has identified key hurdles interfering with the efficacy of cancer vaccines. The vaccination concept still holds promise if positioned appropriately in minimal residual disease and select early disease stage cancer indications. However, in advanced cancer, it must be integrated with complementary immune interventions to ensure reconstruction of a functional immune repertoire and simultaneous blockade of immune inhibiting mechanisms. Vaccination could render complex and integrative immune interventions simpler, safer and more effective. The near future will witness an explosion of activities in the cancer immunotherapy arena, witnessing a rational repositioning of vaccines rather than their extinction.
引用
收藏
页码:1219 / 1234
页数:16
相关论文
共 135 条
  • [21] CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
    Davila, Marco L.
    Kloss, Christopher C.
    Gunset, Gertrude
    Sadelain, Michel
    [J]. PLOS ONE, 2013, 8 (04):
  • [22] Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
    Davis, ID
    Chen, WS
    Jackson, H
    Parente, P
    Shackleton, M
    Hopkins, W
    Chen, QY
    Dimopoulos, N
    Luke, T
    Murphy, R
    Scott, AM
    Maraskovsky, E
    McArthur, G
    MacGregor, D
    Sturrock, S
    Tai, TY
    Green, S
    Cuthbertson, A
    Maher, D
    Miloradovic, L
    Mitchell, SV
    Ritter, G
    Jungbluth, AA
    Chen, YT
    Gnjatic, S
    Hoffman, EW
    Old, LJ
    Cebon, JS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) : 10697 - 10702
  • [23] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [24] Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells
    Dejean, Anne S.
    Beisner, Daniel R.
    Ch'en, Irene L.
    Kerdiles, Yann M.
    Babour, Anna
    Arden, Karen C.
    Castrillon, Diego H.
    DePinho, Ronald A.
    Hedrick, Stephen M.
    [J]. NATURE IMMUNOLOGY, 2009, 10 (05) : 504 - 513
  • [25] Adoptive cell transfer therapy
    Dudley, Mark E.
    Rosenberg, Steven A.
    [J]. SEMINARS IN ONCOLOGY, 2007, 34 (06) : 524 - 531
  • [26] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [27] Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity
    Engels, Boris
    Engelhard, Victor H.
    Sidney, John
    Sette, Alessandro
    Binder, David C.
    Liu, Rebecca B.
    Kranz, David M.
    Meredith, Stephen C.
    Rowley, Donald A.
    Schreiber, Hans
    [J]. CANCER CELL, 2013, 23 (04) : 516 - 526
  • [28] Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010
    Ertl, Hildegund C. J.
    Zaia, John
    Rosenberg, Steven A.
    June, Carl H.
    Dotti, Gianpietro
    Kahn, Jeffrey
    Cooper, Laurence J. N.
    Corrigan-Curay, Jacqueline
    Strome, Scott E.
    [J]. CANCER RESEARCH, 2011, 71 (09) : 3175 - 3181
  • [29] Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
    Fotin-Mleczek, Mariola
    Zanzinger, Kai
    Heidenreich, Regina
    Lorenz, Christina
    Thess, Andreas
    Duchardt, Katharina M.
    Kallen, Karl-Josef
    [J]. JOURNAL OF GENE MEDICINE, 2012, 14 (06) : 428 - 439
  • [30] Gene Signature in Melanoma Associated With Clinical Activity A Potential Clue to Unlock Cancer Immunotherapy
    Gajewski, Thomas F.
    Louahed, Jamila
    Brichard, Vincent G.
    [J]. CANCER JOURNAL, 2010, 16 (04) : 399 - 403